Biotechnology

CureVac doesn’t rule out accelerated approval for COVID-19 vaccine

Active management finds niche in post-pandemic market

Vancouver COVID-19 therapy developer AbCellera eyeing potential IPO as early as fall

The Globe’s stars and dogs for the week

July 9: ‘The government of the people, by Justin Trudeau, for the people.’ Readers take a closer look at the WE Charity contract, plus other letters to the editor

Streetwise newsletter: Best reads of the week

Biotech blind spot: How Canada’s big investors missed the boom happening right now

Top Canadian biotech investor on the firms most likely to turn COVID-19 drug trials into treatments and when a vaccine may arrive

The Globe’s stars and dogs for the week

BioNTech and Pfizer’s COVID-19 vaccine shows potential in human trial

Temasek-led investor group makes $250-million vaccine bet on Germany’s BioNTech

Hamilton biotech Fusion sets IPO price at $17 a share for Friday debut on Nasdaq

Streetwise newsletter: Fusion Pharmaceuticals looks to raise more than $150-million as it launches IPO

Repare soars to largest ever IPO of a Canadian biotech firm in Nasdaq debut

Repare Therapeutics seeks to raise up to US$152-million in Nasdaq share offering

Moderna to start final testing stage of potential coronavirus vaccine in July

Lilly says COVID-19 treatment could be authorized for use as soon as September

Fusion the latest to seek listing on Nasdaq in a flurry of Canadian biotech IPOs

Streetwise newsletter: Reopening companies face growing liability insurance premiums due to coronavirus risk

Quebec to invest $75-million in biotech sector